OncoMatch/Clinical Trials/NCT06342466
Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis
Is NCT06342466 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Bortezomib and Pomalidomide for systemic amyloidosis.
Treatment: Bortezomib · Pomalidomide · Dexamethasone — This is an open-label, multicenter, Phase 2 study in subjects with newly diagnosed or previous treated systemic light chain (AL) amyloidosis. Approximately 40 subjects will receive therapy with bortezomib, pomalidomide, and dexamethasone. The primary outcome is hematologic very good partial response and complete response rate at 6 months.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Endocrine / hormonal
Other
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Lab requirements
Blood counts
absolute neutrophil count (anc) ≥1.0 x 10^9/l, hemoglobin ≥70 g/l, platelets ≥50 x 10^9/l
Kidney function
egfr ≥20 ml/min/ 1.73 m^2
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06342466 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 90 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify